Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.50 |
| ▸ | MVD | P53602 | 4/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.36 |
| ▸ | FNTA | P49354 | 3/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034253 | 0.97 | BTN3A1 (0.47) | BTN3A1MVDGGPS1FNTAPGGT1B | |
| SCHEMBL4946200 | 0.91 | BTN3A1 (0.40) | BTN3A1MVD | |
| SCHEMBL2996800 | 0.90 | BTN3A1 (0.47) | BTN3A1MVDGGPS1FNTAPGGT1B | |
| SCHEMBL4946206 | 0.89 | BTN3A1 (0.39) | BTN3A1MVDFNTAPGGT1BFNTB | |
| SCHEMBL3005883 | 0.89 | BTN3A1 (0.46) | BTN3A1MVDGGPS1FNTAPGGT1B | |
| SCHEMBL2995155 | 0.87 | BTN3A1 (0.45) | BTN3A1MVDGGPS1FNTAFNTB | |
| SCHEMBL2993317 | 0.87 | BTN3A1 (0.45) | BTN3A1MVDGGPS1FNTAFNTB | |
| SCHEMBL2999121 | 0.87 | BTN3A1 (0.45) | BTN3A1MVDGGPS1FNTAFNTB | |
| SCHEMBL3004918 | 0.87 | BTN3A1 (0.45) | BTN3A1MVDGGPS1FNTAFNTB | |
| SCHEMBL2999226 | 0.87 | BTN3A1 (0.45) | BTN3A1MVDGGPS1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1426052-B1 | Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof | INNATE PHARMA (FR) | 2009-09-02 | — | — | EP | claimed |
| US-20050196385-A1 | Methods for producing gamma delta t cells | INNATE PHARAMA (FR) | 2005-09-08 | — | — | US | claimed |
| EP-1476540-A1 | METHODS FOR PRODUCING GAMA DELTA T CELLS | Innate Pharma (FR) | 2004-11-17 | — | — | EP | claimed |
| EP-1426052-A1 | Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof | Innate Pharma (FR) | 2004-06-09 | — | — | EP | claimed |
| WO-2003070921-A1 | METHODS FOR PRODUCING Ϝδ T CELLS | INNATE PHARMA (FR) | 2003-08-28 | — | — | WO | claimed |
| US-20110158954-A1 | METHOD FOR PRODUCING GAMMA DELTA T CELL POPULATION | TAKARA BIO INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100291118-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | INNATE PHARMA, S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-7767842-B2 | Class of γδ T cells activators and use thereof | INNATE PHARMA SA (FR) | 2010-08-03 | — | — | US | disclosed |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | INNATE PHARMA S.A. (FR) | 2010-07-29 | — | — | US | disclosed |
| WO-2010049438-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS FOR THE TREATMENT OF DISEASES | INNATE PHARMA (FR) | 2010-05-06 | — | — | WO | disclosed |
| EP-1569656-B1 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2010-03-03 | — | — | EP | disclosed |
| EP-1569656-A2 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | Innate Pharma (FR) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005077411-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | INNATE PHARMA (FR) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005054258-A2 | NEW CLASS OF GAMMA DELTA T CELLS ACTIVATORS AND USE THEREOF | INNATE PHARMA (FR) | 2005-06-16 | — | — | WO | disclosed |
| WO-2004050096-A2 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2004-06-17 | — | — | WO | disclosed |
| EP-1426052-A1 | Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof | Innate Pharma (FR) | 2004-06-09 | — | — | EP | disclosed |
| EP-1109818-B1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INST NAT SANTE RECH MED (FR) | 2002-11-06 | — | — | EP | disclosed |
| EP-1109818-A1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012519-A1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | IFNG, IL2, ICOS | BTN3A1 288/4885MVD 4043/4885GGPS1 1850/4885 |
| US-20050196385-A1 | Methods for producing gamma delta t cells | IFNG, IL2, ICOS | BTN3A1 500/4885MVD 2813/4885GGPS1 1008/4885 |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | IL2, IL2RA, CD4 | BTN3A1 539/4885MVD 2950/4885GGPS1 1645/4885 |
| US-20100291118-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | CD4, IFNG, NFATC1 | BTN3A1 224/4885MVD 3354/4885GGPS1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.